HR 2927
106th Congress
House
Commerce
Auditing
Congress
Congressional reporting requirements
Debarment of government contractors
Drug industry
Drugs
Finance and Financial Sector
Government Operations and Politics
Health
Intellectual property
Inventions
Medicaid
Medical supplies
Medical technology
Medicare
Patent licenses
Patents
Pharmaceutical research
Prescription pricing
Affordable Prescription Drugs Act
Introduced: September 23, 1999
See on congress.gov
Everywhere this bill has been
9 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 21, 2000
Sponsor introductory remarks on measure. (CR H1127)
Nov 1, 1999
Sponsor introductory remarks on measure. (CR H11148)
Oct 18, 1999
Sponsor introductory remarks on measure. (CR H10154)
Oct 8, 1999
Referred to the Subcommittee on Health and Environment.
Oct 4, 1999
Referred to the Subcommittee on Courts and Intellectual Property.
Sep 30, 1999
Sponsor introductory remarks on measure. (CR H9176-9177)
Sep 23, 1999
Referred to the Committee on the Judiciary, and in addition to the Committee on Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sep 23, 1999
Sponsor introductory remarks on measure. (CR H8622)
Sep 23, 1999
Introduced in House
Plain-English summary
Affordable Prescription Drugs Act - Amends Federal patent law to grant the Secretary of Health and Human Services the right to establish compulsory licensing (without authorization of the right holder) for nonexclusive, nonassignable use of certain patented medical inventions upon a determination that: (1) the patent holder, contractor, exclusive licensee, or assignee has not taken, or is not expected to take within a reasonable time, effective steps to achieve practical application of the subject invention in a field of use; (2) such compulsory license is necessary to alleviate health or safety needs which are not adequately satisfied by the patent holder, contractor, licensee, or assignee; or (3) the patented material is priced higher than may be reasonably expected based on criteria developed by the Secretary of Commerce.
Requires any person engaged in the manufacture and sale of any new drug or new animal drug approved under the Federal Food, Drug, and Cosmetic Act, for which a patent is still in effect, to report annually to Congress an audit of all financial information relevant to that drug's pricing nationally and internationally, including research and development costs, sufficient to assess the reasonableness of that pricing. Requires disqualification from participation in Federal programs as a penalty for noncompliance with this reporting requirement.
What's happening now
Sponsor introductory remarks on measure. (CR H1127)